Sirolimus looks promising in DME

Article

MacuSight has announced positive interim data from a Phase I study of its proprietary formulation of sirolimus (originally known as rapamycin) for the treatment of chronic, clinically significant diabetic macular oedema (DME).

MacuSight has announced positive interim data from a Phase I study of its proprietary formulation of sirolimus (originally known as rapamycin) for the treatment of chronic, clinically significant diabetic macular oedema (DME).

The randomized, open-label study of 50 subjects with DME was designed to investigate the safety, tolerability and biological activity of sirolimus delivered either by subconjunctival or intravitreal injection. The trial included ten treatment arms with subjects receiving one of five doses.

At 45 and 90 days post-treatment, subjects receiving the two lowest doses by subconjunctival injection showed mean improvements in visual acuity (VA) of 8.5 and 7.4 letters, respectively. This group also demonstrated anatomical improvements, with a mean decrease in foveal thickness consistent with the observed functional improvements in VA.

Preliminary data at 180 days post-treatment, suggests that initial improvements in VA and foveal thickness reductions are maintained or enhanced over time in many patients.

MacuSight has already completed enrolment of a second Phase I trial, which will examine sirolimus in patients with exudative age-related macular degeneration.

Sirolimus is a potent, broad-acting compound that has demonstrated the ability to combat disease through multiple mechanisms of action including immunosuppressive, anti-angiogenic, anti-migratory, anti-proliferative, anti-fibrotic and anti-permeability activity.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.